JARID1B Protein Expression and Prognostic Implications in Uveal Melanoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 8, 2012, Pages 4442-4449

  Radberger, Patrik ^a   Radberger, Agatha ^a   Vladimir, J N Bykov ^a   Seregard, Stefan ^b   Economou, Mario A ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

JUMONJI AT RICH INTERACTIVE DOMAIN 1B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CILIARY BODY EPITHELIUM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR VOLUME; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; EYE ENUCLEATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; REPRESSOR PROTEINS; SURVIVAL RATE; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 84863746494     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9296     Document Type: Article

References (52)

1. Bergman L, Seregard S, Nilsson B, Ringborg U, Lundell G, Ragnarsson-Olding B. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002;43:2579-2583.
2. Inskip PD. Frequent radiation exposures and frequencydependent effects: the eyes have it. Epidemiology. 2001;12: 1-4.
3. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-965.
4. Harbour JW. Clinical overview of uveal melanoma: introduction to tumors of the eye. In: Albert DM, Polans A, eds. Ocular Oncology. New York, NY: Marcel Dekker; 2003:1-18.
5. Strickland D, Lee JA. Melanomas of eye: stability of rates. Am J Epidemiol. 1981;113:700-702.
6. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670-676.
7. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol. 1978;86:76-80.
8. Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer. 1974;34:1001-1004.
9. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991; 98:383-389; discussion 390.
10. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651-4659.
11. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334-336.
12. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143-150, ix.
13. Garcia-Alvarez C, Saornil MA, Munoz MF, et al. Ocular conservation in patients with uveal melanoma by a multimodality approach to treatment. Acta Ophthalmol Scand. 2007;85(suppl 240):0. doi: 10.1111/j.1600-0420.2007. 01062_3408.x
14. Shildkrot Y, Wilson MW. Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease. Curr Opin Ophthalmol. 2009;20:504-510.
15. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008;34:247-258.
16. Labialle S, Dayan G, Gambrelle J, et al. Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives. Melanoma Res. 2005;15:257-266.
17. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:107-108.
18. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
19. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncology. 2004;22: 2438-2444.
20. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
21. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin Oncol. 2008;26:2890-2894.
22. Thill M, Berna MJ, Grierson R, et al. Expression of CD133 and other putative stem cell markers in uveal melanoma. Melanoma Res. 2011;21:405-416.
23. Kalirai H, Damato BE, Coupland SE. Uveal melanoma cell lines contain stem-like cells that self-renew, produce differentiated progeny, and survive chemotherapy. Invest Ophthalmol Vis Sci. 2011;52:8458-8466.
24. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141: 583-594.
25. Christensen J, Agger K, Cloos PA, et al. RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3. Cell. 2007;128:1063-1076.
26. Seward DJ, Cubberley G, Kim S, et al. Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins. Nat Struct Mol Biol. 2007;14:240-242.
27. Tan K, Shaw AL, Madsen B, Jensen K, Taylor-Papadimitriou J, Freemont PS. Human PLU-1 Has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9. J Biol Chem. 2003;278:20507-20513.
28. Xiang Y, Zhu Z, Han G, et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A. 2007;104:19226-19331.
29. Yamane K, Tateishi K, Klose RJ, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell. 2007;25:801-812.
30. Scibetta AG, Santangelo S, Coleman J, et al. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol. 2007;27:7220-7235.
31. Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br Journal Cancer. 2000; 82:818-822.
32. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science. 1992;258:1148-1152.
33. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43:2845-2851.
34. Merbs SL, Sidransky D. Analysis of p16 (CDKN2/MTS-1/ INK4A) alterations in primary sporadic uveal melanoma. Invest Ophthalmol Vis Sci. 1999;40:779-783.
35. Tobal K, Warren W, Cooper CS, McCartney A, Hungerford J, Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer. 1992;66:900-904.
36. Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Derm. 1995;133:23-31.
37. Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood. 1997; 89:1376-1382.
38. Polkowski W, Baak JP, van Lanschot JJ, et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol. 1998;184:161-168.
39. Polkowski W, Meijer GA, Baak JP, et al. Reproducibility of p53 and Ki-67 immunoquantitation in Barrett's esophagus. Anal Quant Cytol Histol. 1997;19:246-254.
40. La Porta C. Cancer stem cells: lessons from melanoma. Stem Cell Rev. 2009;5:61-65.
41. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-768.
42. Hayami S, Yoshimatsu M, Veerakumarasivam A, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 2010; 9:59.
43. Held M, Bosenberg M. A role for the JARID1B stem cell marker for continuous melanoma growth. Pigment Cell Melanoma Res. 2010;23:481-483.
44. Barrett A, Madsen B, Copier J, et al. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/ testis antigen? Int J Cancer. 2002;101:581-588.
45. Belmar-Lopez C, Mancheno-Corvo P, Saornil MA, et al. Uveal vs. cutaneous melanoma. Origins and causes of the differences. Clin Transl Oncol. 2008;10:137-142.
46. Lu PJ, Sundquist K, Baeckstrom D, et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem. 1999;274:15633-15645.
47. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-1678.
48. Didolkar MS, Elias EG, Barber NA, Moore RH. Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck. Am J Surg. 1980;140:522-526.
49. Machalinska A, Zuba-Surma EK. Stem cells in adult retina-current state of research, future therapeutic prospects [in Polish]. Klin Oczna. 2009;111:253-257.
50. Mitashov VI. Multipotent and stem cells in the developing, definitive, and regenerating vertebrate eye [in Russian]. Izv Akad Nauk Ser Biol. 2001;6:717-727.
51. Ohta K, Ito A, Tanaka H. Neuronal stem/progenitor cells in the vertebrate eye. Dev Growth Diff. 2008;50:253-259.
52. Sun G, Asami M, Ohta H, Kosaka J, Kosaka M. Retinal stem/ progenitor properties of iris pigment epithelial cells. Dev Biol. 2006;289:243-252.